MedTrace Logo

Study of Induction of Hypothyroxinemia Adjunct to Conventional Therapies in GBM Patients

NCT02654041 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2018-03-22

No results posted yet for this study

Summary

The objective of the study is to assess the safety and efficacy of treatment with hypothyroxinemia adjunct to conventional therapies in GBM patients.

Conditions

  • Glioblastoma Multiforme (GBM)

Interventions

DRUG

Combined T3 and Methimazole treatment

Oral administration of T3 and Methimazole

Sponsors & Collaborators

  • Tel-Aviv Sourasky Medical Center

    collaborator OTHER_GOV

  • Musli Thyropeutics Ltd.

    lead INDUSTRY

Principal Investigators

  • Deborah T Blumenthal, MD · Tel-Aviv Medical Center, Israel

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2017-06-30
Completion
2017-06-30

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02654041 on ClinicalTrials.gov